Finanzen von Skye Bioscience Inc (SKYE)SKYESkye Bioscience Inc

Evaluating the bottom line, Skye Bioscience, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -233.87%, provide a clear picture of how effectively SKYE converts its operational activities into shareholder value.

In the context of the broader market, SKYE competes directly with industry leaders such as AIM and ALZN. With a market capitalization of $7.97M, it holds a significant position in the sector. When comparing efficiency, SKYE's gross margin of N/A stands against AIM's 80.77% and ALZN's N/A. Such benchmarking helps identify whether Skye Bioscience, Inc. is trading at a premium or discount relative to its financial performance.

Skye Bioscience has consistently reported negative net income, with Q4 2025 showing a loss of $14.4 million, up from $9.7 million in Q4 2024. The company's EPS for the same quarter was -0.36, missing expectations by $0.06, indicating challenges in profitability.